It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 26.1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Th ...

Affirm TodayAFRMAffirm$58.23 +2.52 (+4.52%) 52-Week Range$22.25▼$82.53Price Target$64.15Add to WatchlistThe "Buy Now, Pay Later" (BNPL) wave continues to reshape how consumers approach purchases, and Affirm Holdings NASDAQ: AFRM is a significant force within this transformation. Offering flexible payment solutions, Affirm recently reported a noteworthy financial milestone, marking a return to profitability with a quarterly GAAP net income. This achievement, alongside ongoing strong growth, positions Affirm ...

Press release Ecully, June 6, 2025 – 6.00 p.m. SPINEWAY Minutes of the General Meeting of June 4, 2025 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69). The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2 ...

THIS DOCUMENT IS AN UNOFFICIAL ENGLISH-LANGUAGE TRANSLATION OF THE PRESS RELEASE REGARDING THE OFFER DOCUMENT (NOTE D’INFORMATION) WHICH WAS FILED WITH THE FRENCH AUTORITÉ DES MARCHÉS FINANCIERS ON JUNE 5, 2025. IN THE EVENT OF ANY DIFFERENCES BETWEEN THIS UNOFFICIAL ENGLISH- LANGUAGE TRANSLATION AND THE OFFICIAL FRENCH OFFER DOCUMENT, THE OFFICIAL FRENCH OFFER DOCUMENT SHALL PREVAIL. PRESS RELEASE DATED JUNE 6, 2025 AVAILABILITY OF THE INFORMATION DOCUMENT PREPARED BY TARKETT PARTICIPATION IN THE CONTEXT O ...

Cloud3 Ventures Inc. Accelerates Growth Across AI, Blockchain, and Mental Wellness Ecosystems with Strategic Holdings and Expansion of the LIF3 PlatformJune 06, 2025 12:31 PM EDT | Source: Cloud3 Ventures Inc.Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Cloud3 Ventures Inc. (CSE: CLDV) (OTCQB: CLDVF) (FSE: WQ40) ("Cloud3 Ventures" or the "Company"), a bold venture holding company pioneering blockchain, digital assets, artificial intelligence, and clean energy, today shares an update on ...

Foussemagne (France), June 6, 2025 – 6 p.m. CEST McPhy Energy (“McPhy”) announces the opening of a judicial reorganization (redressement judiciaire) as of 4 June, 2025 by the Belfort Commercial Court (the “Court”)1. In this context, the Court has appointed: SCP Abitbol & Rousselet, represented by Maître Joanna Rousselet (formerly the Court-appointed conciliator (concliateur) for the Company2), as judicial administrator (administrateur judiciaire) with an assistance mission; andMaître Flavien Marchal, as cr ...

Reference is made to the stock exchange notice from IDEX Biometrics ASA (the “Company”) on 11 April 2025 regarding key information relating to share consolidation and change of ISIN as resolved by the 11 April 2025 Extraordinary General Meeting in the Company (the “EGM”). The effective date of the share consolidation was stated to be 11 June 2025 or such later date as determined by the board of directors of the Company (the “Board”). Reference is also made to the subsequent offering resolved by the EGM (the ...

Reference is made to the stock exchange notice from IDEX Biometrics ASA (the “Company”) on 11 April 2025 regarding key information relating to share consolidation and change of ISIN as resolved by the 11 April 2025 Extraordinary General Meeting in the Company (the “EGM”). The effective date of the share consolidation was stated to be 11 June 2025 or such later date as determined by the board of directors of the Company (the “Board”). Reference is also made to the subsequent offering resolved by the EGM (the ...

Core Points - The U.S. FDA has approved Phathom Pharmaceuticals' Citizen Petition, recognizing a 10-year exclusivity period for VOQUEZNA (vonoprazan) tablets, extending through May 3, 2032 [1] Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [2] - The company has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), marketed as VOQUEZNA for various gastrointestinal conditions [2] Product Information - VOQUEZNA is indicated for the relief of heartburn associated with Non-Erosive GERD, healing and maintenance of Erosive GERD, and treatment of H. pylori infection in adults [2]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...